July 23, 2025Open Access

Data from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Chemoimmunotherapy resulted in a median overall survival of 22.3 months compared to 17.0 months for chemotherapy alone.
Liver metastases and prior antimicrobial therapy significantly reduced the efficacy of chemoimmunotherapy in the studied patients.
The retrospective study analyzed data from 851 patients with advanced non-small cell lung cancer across 19 institutions in Japan.
Identifying key factors like liver metastases and antibiotic use is essential for improving treatment strategies in these patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cohort study shows chemoimmunotherapy enhances overall survival in advanced NSCLC, indicating liver metastases affect treatment efficacy.

Hata et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark